In Brief: Amylin pramlintide
Executive Summary
Amylin pramlintide: Firm has no provision for interim analyses of its pivotal studies for pramlintide in type 2 diabetes patients. "Amylin and Johnson & Johnson have not planned any interim analyses nor made a decision on the release of any interim analyses of the data from the four ongoing pivotal trials for pramlintide," the company said in a letter to the "The Pink Sheet." Results from the studies are expected by the second half of 1998 and an NDA is slated for late 1998 ("The Pink Sheet" Aug. 25, T&G-3)...